期刊文献+

^18 F-FDG PET/CT对原发性乳腺癌诊断和淋巴结分期的临床价值 被引量:6

Performance of ^18 F-FDG PET/CT in the detection of primary breast cancer and staging of the regional lymph nodes
原文传递
导出
摘要 目的 评价^18 F-脱氧葡萄糖(^18 F-FDG)PET/CT对原发性乳腺癌诊断和淋巴结分期的临床价值。方法 临床拟诊为乳腺癌的27例女性患者,手术前分别行乳腺钼靶X线和^18 F-FDG PET/CT检查。全部患者均行手术治疗,共切除32个病灶,23例患者接受了腋淋巴结廓清术,并行病理学诊断。结果 32个病灶中,25个为乳腺癌病灶,7个为良性病变。^18F-FDG PET/CT诊断的敏感度为80.0%,特异度为71.4%。T1期病灶8个,PET/CT诊断阳性6个;T2期病灶14个,PET/CT诊断阳性12个;邸期病灶2个,PET/CT均诊断阳性。对区域淋巴结转移,PET/CT诊断的敏感度为60.0%,特异度为84.6%,诊断准确度为73.9%。结论 对于怀疑多中心乳癌、病期较晚、需要全面评价区域淋巴结状态或疑有远处转移的患者,PET/CT具有优势,对乳腺癌的分期有重要帮助,但尚不适宜于作为乳腺癌的常规检查。 Objective To evaluate the performance of ^18F-FDG PET/CT in the detection of primary breast cancer, and the staging of regional lymph nodes. Methods Twenty four females with highly suspected breast cancer, underwent PET/CT imaging of the breast preoperatively. All the patients received no treatment at admission. Three nuclear medicine physicians analyzed the image and made the diagnosis. 32 breast lesions were evaluated by histology, revealing 25 breast carcinomas and 7 benign pathological changes. 23 patients had histological diagnosis of the breast tumor and regional lymph nodes. Results 20 of 25 breast carcinomas were successfully diagnosed by FDG-PET/CT. The sensitivity was 80% and specificity was 71.4%. No Tis breast carcinoma was detected. 75.0% of T1 breast carcinomas were detected, and with 85.7% of stage T2, 100.0% of T3. 10 patients were proved to have lymph node metastasis, and PET/CT got a sensitivity of 60.0%. As to a suspicions distant metastasis, PET/CT convinced the diagnosis. Conclusion As a noninvasive technique, FDG PET/GT appears to be a useful method in staging patient with breast cancer, especially in cases in which the lesion is hard to predict by routine examination. But the accuracy of FDG PET/CT seems to be not high enough to identify patients who might avoid axillary lymph nodes dissection. In the detection of breast lesions, PET/CT doesn't seem to have a high sensitivity, especially in early stage breast cancers. The high cost and the space resolution limit its use as a routine diagnostic method of breast cancer.
出处 《中华肿瘤杂志》 CAS CSCD 北大核心 2007年第3期206-209,共4页 Chinese Journal of Oncology
关键词 乳腺肿瘤 PET/CT ^18 F-FDG Breast neoplasms PET/CT ^18 F-FDG
  • 相关文献

参考文献11

  • 1杨玲,李连弟,陈育德,D.M.Parkin.中国乳腺癌发病死亡趋势的估计与预测[J].中华肿瘤杂志,2006,28(6):438-440. 被引量:281
  • 2Kpans DB, Feig SA. False positive rate of screening mammography.N Engl J Med, 1998, 339: 562-564.
  • 3Kopans DB. The positive predictive value of mammography. AJR Am J Roentgenol, 1992, 158: 521-526.
  • 4Meyer JE, Eberlein TJ, Stomper PC, et al. Biopsy of occult breast lesions: analysis of 1261 abnormalities. JAMA, 1990, 263: 2341-2343.
  • 5American College of Radiology (ACR). Breast Imaging Reporting and Data System (BI-RADS). 3rd ed. Reston: Am College of Radiol, 1998. 1-90.
  • 6Fisher B. Laboratory and clinical research in breast cancer-a personal adventure: the David A. Karnofsky memorial lecture.Cancer Res, 1980, 40: 3863-3874.
  • 7张保宁,邵志敏,乔新民,李波,姜军,杨名添,王水,宋三泰,张斌,杨红健.中国乳腺癌保乳治疗的前瞻性多中心研究[J].中华肿瘤杂志,2005,27(11):680-684. 被引量:246
  • 8Avril N, Rose CA, Schelling M, et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol, 2000, 18: 3495-3502.
  • 9Antoch G, Saoudi N, Kuehl H, et al. Accuracy of whole-body dualmodality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol,2004, 22 : 4357-4368.
  • 10Bombardieri E, Aktolun C, Baum RP, et al. FDG PET: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging, 2003,30: BP115-124.

二级参考文献29

  • 1李连弟,鲁凤珠.1990—1992年中国恶性肿瘤死亡流行分布情况分析[J].中华肿瘤杂志,1996,18(6):403-407. 被引量:227
  • 2李连弟,鲁凤珠,张思维,牧人,孙秀娣,皇甫小梅,孙杰,周有尚,欧阳宁慧,饶克勤,陈育德,孙爱明,薛志福,夏毅.中国恶性肿瘤死亡率20年变化趋势和近期预测分析[J].中华肿瘤杂志,1997,19(1):3-9. 被引量:868
  • 3全国肿瘤防治研究办公室 卫生部卫生统计信息中心.中国恶性肿瘤危险因素研究[M].北京:中国协和医科大学出版社,2003..
  • 4Bedwinek J. Treatment of stage I and Ⅱ adenocarcinoma of the breast by tumor excision and irradiation. Int J Radiat Oncol Biol Phys, 1981,7: 1553-1559.
  • 5Park CC, Mitsumori M, Nixon A, et al. Outcome at 8 years after breast-conserving surgery and radiation therapy for invasive breast cancer: influence of margin status and systemic therapy on local recurrence. J Clin Oncol,2000, 18: 1668-1675.
  • 6Smitt MC, Nowels KW, Zdeblick MJ, et al. The importance of the lumpectomy surgical margin status in long-term results of breast conservation. Cancer, 1995,76:259-267.
  • 7Bartelink H, Horiot JC, Poortmans P, et al. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med,2001,345:1378-1387.
  • 8National Institutes of Health. NIH consensus conference on the treatment of early-stage breast cancer. JAMA,1991,265:391-395.
  • 9Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med,2002,347: 1233-1241.
  • 10Liljegren G, Holmberg L, Bergh J, et al. 10-Year results after sector resection with or without postoperative radiotherapy for stage I breast cancer: a randomized trial. J Clin Oncol,1999,17:2326-2333.

共引文献520

同被引文献83

  • 1时开元,钱超文,陈丽羽,王立平,陈道宝.导丝定位在经乳晕旁切口切除乳腺隐匿性病灶中的应用[J].医学影像学杂志,2011,21(5):692-694. 被引量:3
  • 2吴湖炳,王全师,王明芳,王欣璐,郭晓君.PET/CT诊断恶性肿瘤及其转移灶的价值[J].中华核医学杂志,2005,25(2):84-86. 被引量:40
  • 3江泽飞,徐兵河,宋三泰,孙燕.乳腺癌内分泌治疗的基本共识[J].中华肿瘤杂志,2006,28(3):238-239. 被引量:49
  • 4杨玲,李连弟,陈育德,D.M.Parkin.中国乳腺癌发病死亡趋势的估计与预测[J].中华肿瘤杂志,2006,28(6):438-440. 被引量:281
  • 5贾丽,于金明,王仁本,巩合义,李金丽,焦玉红.^(18)F-FDG PET/CT对乳腺癌新辅助化疗疗效预测的价值[J].中国肿瘤临床与康复,2006,13(3):215-218. 被引量:10
  • 6Althuis MD, Fergenbaum JH, Garcia-Closas MG. Etiology of hormone receptor-defined breast cancer:A systematic leview of the literature [J]. Cancer Epidemiol Biomarkers Prey, 2004, 13(10):1558-1568.
  • 7Early Breast Cancer Trialst's Collaborative Group (EBCTCG).Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of randomized trials[J]. Lancet, 2005, 365(9472): 1687-1717.
  • 8Coates AS, Keshaviah A, Thtirlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98[J]. J Clin Oncol, 2007, 25(5):486-492.
  • 9Forbes JF, Cuzick J, Buzdar A, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial[J]. Lancet Oncol, 2008, 9(1):45-53.
  • 10Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole verus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: result of a phase Ⅲ study of the international Letrozole Breast Cancer Group [J]. J Clin Oncol, 2001, 19(10): 2596-2606.

引证文献6

二级引证文献45

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部